MedTrace Logo

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

NCT00692146 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-06-06

No results posted yet for this study

Summary

A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

Conditions

  • Capsaicin Evoked Pain
  • Heat Sensitivity

Interventions

DRUG

AZD1386

Oral solution fixed dose (95 mg given orally on two occasions)

DRUG

Placebo

Oral solution fixed dose (95 mg given orally on two occasions)

Sponsors & Collaborators

Principal Investigators

  • Agneta Berg · AstraZeneca R&D Södertälje

  • Ingemar Bylesjö · AstraZeneca R&D CPU Karolinska University Hospital, Stockholm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692146 on ClinicalTrials.gov